Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Xếp hạng trong cổ phiếu #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Giá cổ phiếu
$193.62
Vốn hóa thị trường
$150.08B
Thay đổi (1 ngày)
2.76%
Thay đổi (1 năm)
184.69%
Quốc gia
GB
Giao dịch AstraZeneca PLC (AZN)

Danh mục

Lịch sử giá cổ phiếu của AstraZeneca PLC (AZN)
Giá đóng cửa cao nhất: $191.96 vào 2026-03-01

Giá đóng cửa thấp nhất: $4.88 vào 1993-05-01
Lịch sử giá cổ phiếu của AstraZeneca PLC từ 1993 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 8.71%
2025 36.83%
2024 1.90%
2023 -4.59%
2022 21.85%
2021 9.28%
2020 5.13%
2019 27.66%
2018 15.57%
2017 23.32%
2016 -20.21%
2015 -6.16%
2014 24.29%
2013 21.08%
2012 4.55%
2011 -3.37%
2010 2.75%
2009 17.01%
2008 -13.01%
2007 -18.66%
2006 15.35%
2005 24.93%
2004 -17.36%
2003 28.70%
2002 -19.27%
2001 -10.34%
2000 18.78%
1999 -3.47%
1998 28.64%
1997 25.37%
1996 38.87%
1995 45.94%
1994 12.44%
1993 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
$885.05 17.33%
US
$241.79 56.64%
US
$212.48 18.64%
US
$150.20 37.22%
CH
$117.65 48.60%
US